Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT06001788
Trial Phases:	Phase I	Protocol IDs:	KO-MEN-008 (primary) NCI-2023-06933
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Kura Oncology, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06001788

Summary

The safety, tolerability, and antileukemic response of ziftomenib in combination with
standard of care treatments for patients with relapsed/refractory acute myeloid leukemia
will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and
gilteritinib.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.